DESENVOLVIMENTO DE UMA FORMULAÇÃO SEMI-SÓLIDA CONTENDO NANOCÁPSULAS DE DEXAMETASONA: ESTUDO DE ESTABILIDADE E AVALIAÇÃO DA LIBERAÇÃO IN VITRO

• Autor(a) principal: Ferrony, Daniel de Azevedo
• Data de Publicação: 2018
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional Universidade Franciscana
• Texto Completo: http://tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/267; http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/314
• topic: Dexametasona; Nanocápsulas; Estabilidade; Liberação; Psoríase; Nanociências; Dexamethasone; Nanocapsule; Stability; Realeasing; Psoriases; CNPQ::ENGENHARIAS

Anti-inflammatory, corticosteroids are largely applied for the lesion topical treatment, which many times require treatment for a prolonged period increasing the risks of collateral damage. This work has as its objective the development of a semi-solid formulation of topical use containing dexamethasone in the nanoencapsulated (CGNCDEXA), for the psoriases treatment. For that, after the development of a semisolid formulation and the incorporation of dexamethasone nanocapsules, stability studies were carried out, thermical analysis, a releasing studies of the drug. The samples were stored at 40°C (±2°C) and 75% UR (±5%) for 150 days, being analyzed in intervals of 30 days concerning the organoleptic characteristics, pH, viscosity, spreading and drug. For the releasing studies modified Franz cells were used. All the analyzed parameters were compared to formulations containing the free form drug. The CGNCDEXA organoleptical characteristics remained stable for a period of 60 days. For the formulation containing the free drug, the alterations were noticeable from the first month of analysis. Organoleptical characteristic alterations were observed for both formulations, being more intense in the formulation containing the free form drug. The pH values for both formulations were kept around 6.0 at the end of 150 days of experiment. The CGNCDEXA formulations presented pseudoplastic rheological behavior, while the semi-solid formulation containing the free form drug (CGDEXA) presented plastic behavior. The viscosity values of the formulation of CGNCDEXA presented significant difference (p≤0,05) in relation to its initial values (7416 mPa) and after 150 days (2315 mPa). The viscosity values of the CGDEXA formulation also presented significant differences (p≤0,05) in relation to the initial values (12730 mPa) and final, after 150 days (3170 mPa) of analysis. The spreading values of the formulation of CGNCDEXA did not present significant difference (p≥0,05) in relation to its initial values (6184 mm²) and final (6408 mm²). However, for the CGDEXA formulation was observed a significant difference (p≤0,05) in relation to its initial values (4364 mm²) and final (6467 mm²) of spreading. The dexamethasone concentration decreased for both formulations during the 150 days of experiment. Through the thermical analysis (DSC and TG) it was possible to evidence the dexamethasone fusion, when it was found in the free form incorporated in the gel cream formulation. However, the thermical analysis of the gel cream formulation containing dexamethasone in the nanoencapsuled, did not evidence its fusion indicating a drug protection by the nanostructured system. The releasing flow and the total dexamethasone concentration released for the CGNCDEXA formulations were significantly smaller (p≤0,05)than the formulations containing a free form drug, thus suggesting, a slower release of the nonencapsuled dexamethasone. Through the results, it is possible to conclude that the dexamethasone nanocapsule corporation in a gel cream formulation containing emollient components presented proper physicalchemical characteristics, representing viability for the preparation of this kind of formulation.